Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2018 1
2019 1
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.
Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, Högl B, Lewerenz J, Erro ME, Garcia-Monco JC, Nigro P, Tambasco N, Patalong-Ogiewa M, Erdler M, Macher S, Berger-Sieczkowski E, Höftberger R, Geis C, Hutterer M, Milán-Tomás A, Martin-Bastida A, Manzanares LL, Quintas S, Höglinger GU, Möhn N, Schoeberl F, Thaler FS, Asioli GM, Provini F, Plazzi G, Berganzo K, Blaabjerg M, Brüggemann N, Farias T, Ng CF, Giordana C, Herrero-San Martín A, Huebra L, Kotschet K, Liendl H, Montojo T, Morata C, Perez JP, Puertas I, Seifert-Held T, Seitz C, Simabukuro MM, Tellez N, Villacieros-Álvarez J, Willekens B, Sabater L, Iranzo A, Cano JS, Dalmau J, Graus F. Gaig C, et al. Among authors: berger sieczkowski e. Neurology. 2021 Aug 11;97(14):e1367-81. doi: 10.1212/WNL.0000000000012639. Online ahead of print. Neurology. 2021. PMID: 34380749
Pulse-synchronous torsional nystagmus.
Milenkovic I, Sycha T, Berger-Sieczkowski E, Rommer P, Czerny C, Wiest G. Milenkovic I, et al. Among authors: berger sieczkowski e. Pract Neurol. 2021 Oct;21(5):445-447. doi: 10.1136/practneurol-2021-003027. Epub 2021 Jul 16. Pract Neurol. 2021. PMID: 34272326
Ocular Motor Abnormalities in Anti-IgLON5 Disease.
Macher S, Milenkovic I, Zrzavy T, Höftberger R, Seidel S, Berger-Sieczkowski E, Berger T, Rommer PS, Wiest G. Macher S, et al. Among authors: berger sieczkowski e. Front Immunol. 2021 Sep 30;12:753856. doi: 10.3389/fimmu.2021.753856. eCollection 2021. Front Immunol. 2021. PMID: 34659261 Free PMC article.
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, Lagler H, Oesterreicher Z, Wulkersdorfer B, Lührs P, Galabova G, Schwenke C, Mader RM, Medori R, Landlinger C, Kutzelnigg A, Staffler G. Zeitlinger M, et al. Among authors: berger sieczkowski e. Eur J Clin Pharmacol. 2021 Oct;77(10):1473-1484. doi: 10.1007/s00228-021-03149-2. Epub 2021 May 10. Eur J Clin Pharmacol. 2021. PMID: 33969434 Free PMC article. Clinical Trial.